Published in Hepatitis Weekly, April 11th, 2005
Genelabs reported 2004 revenues of $5.6 million, compared to $2.9 million for 2003. Operating expenses were $21.6 million in 2004 compared to $23.3 million in 2003. For 2004, the company reported a net loss of $13.5 million, or $0.15 per share, compared to a net loss of $19.8 million, or $0.31 per share, in 2003.
The company also reported financial results for the fourth quarter of 2004. Revenues for the 3 months ended December 31, 2004, were $3.8 million, compared to revenues of $0.7 million for the 3 months ended December 31, 2003. Operating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.